ATE373086T1 - Enzyme des auf die lysosomen gerichteten weges - Google Patents

Enzyme des auf die lysosomen gerichteten weges

Info

Publication number
ATE373086T1
ATE373086T1 AT00961335T AT00961335T ATE373086T1 AT E373086 T1 ATE373086 T1 AT E373086T1 AT 00961335 T AT00961335 T AT 00961335T AT 00961335 T AT00961335 T AT 00961335T AT E373086 T1 ATE373086 T1 AT E373086T1
Authority
AT
Austria
Prior art keywords
lysosomes
enzymes
pathway directed
methods
pathway
Prior art date
Application number
AT00961335T
Other languages
English (en)
Inventor
M Canfield William
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE373086T1 publication Critical patent/ATE373086T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1223—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04045—N-Acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase (3.1.4.45)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00961335T 1999-09-14 2000-09-14 Enzyme des auf die lysosomen gerichteten weges ATE373086T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15383199P 1999-09-14 1999-09-14

Publications (1)

Publication Number Publication Date
ATE373086T1 true ATE373086T1 (de) 2007-09-15

Family

ID=22548927

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961335T ATE373086T1 (de) 1999-09-14 2000-09-14 Enzyme des auf die lysosomen gerichteten weges

Country Status (10)

Country Link
US (8) US6534300B1 (de)
EP (1) EP1224266B1 (de)
JP (1) JP2003509043A (de)
AT (1) ATE373086T1 (de)
AU (1) AU783224B2 (de)
BR (1) BR0014514A (de)
CA (1) CA2383217C (de)
DE (1) DE60036395T2 (de)
MX (1) MXPA02002901A (de)
WO (1) WO2001019955A2 (de)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6849257B2 (en) 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
EP2767291B1 (de) 2000-07-18 2016-09-14 Duke University Behandlung der Glykogenspeicherkrankheit Typ II
EP1782825B1 (de) * 2000-07-18 2014-09-10 Duke University Behandlung der Glykogenspeicherkrankheit typ II
AU2012200674B2 (en) * 2000-08-18 2014-04-24 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7001994B2 (en) * 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7749971B2 (en) * 2001-02-20 2010-07-06 Bedwell David M Aminoglycoside treatment for lysosomal storage diseases
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) * 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
FR2825268B1 (fr) * 2001-05-31 2004-09-17 Oreal Composition cosmetique comprenant des particules de carbonate de calcium et des agents de conditionnement
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ES2291507T3 (es) * 2001-10-19 2008-03-01 MERCK & CO., INC. Moduladores de receptor de androgenos y procedimientos de uso de los mismos.
US7368108B2 (en) * 2001-11-28 2008-05-06 Neose Technologies, Inc. Glycopeptide remodeling using amidases
US20030133924A1 (en) * 2001-12-21 2003-07-17 Novazyme Pharmaceuticals, Inc. Highly phosphorylated acid beta-glucocerebrosidase and methods of treating gaucher's disease
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
EP1336411A1 (de) * 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verbindungen und Methoden zur Verbesserung der Enzymersatz-Therapie bei lysosomalen Speicherkrankheiten
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
PL1615945T3 (pl) * 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1613261A4 (de) * 2003-04-09 2011-01-26 Novo Nordisk As Intrazelluläre bildung von peptidkonjugaten
JP2007523630A (ja) 2003-05-09 2007-08-23 ネオス テクノロジーズ インコーポレイテッド ヒト成長ホルモングリコシル化突然変異体の組成と調合法
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
NZ548123A (en) 2004-01-08 2010-05-28 Novo Nordisk As O-linked glycosylation of peptides
US20080014188A1 (en) * 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
JP2008538181A (ja) * 2005-03-30 2008-10-16 ネオス テクノロジーズ インコーポレイテッド 昆虫細胞系において増殖させたペプチドを生産するための製造方法
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP3782655A1 (de) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. Verfahren zur behandlung der pompe-krankheit unter verwendung von 1-deoxynojirimycin und derivaten
EP2975135A1 (de) 2005-05-25 2016-01-20 Novo Nordisk A/S Glykopegylierter Faktor IX
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
SI1945665T1 (sl) * 2005-10-21 2012-03-30 Genzyme Corp Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
HRP20120994T1 (hr) 2006-02-07 2012-12-31 Shire Human Genetic Therapies, Inc. Stabilizirana smjesa glukocerebrozidaze
EP2049144B8 (de) * 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen
EP2054521A4 (de) 2006-10-03 2012-12-19 Novo Nordisk As Verfahren zur reinigung von polypeptid-konjugate
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
EP2099523A2 (de) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Verfahren zur behandlung von pompe-krankheit
WO2008089403A2 (en) 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
JP2010516784A (ja) * 2007-01-29 2010-05-20 ユニバーシティ・オブ・オックスフォード 糖免疫原
EP2155197A4 (de) * 2007-03-09 2011-10-12 Link Medicine Corp Behandlung von lysosomalen speicherkrankheiten
HRP20130382T1 (hr) 2007-04-03 2013-05-31 Biogenerix Ag Postupci lijeäśenja pomoä†u glikopegiliranog g-csf
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
US7722865B2 (en) 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
PL2257311T3 (pl) 2008-02-27 2014-09-30 Novo Nordisk As Koniugaty cząsteczek czynnika VIII
JP5627571B2 (ja) 2008-05-07 2014-11-19 バイオマリン ファーマシューティカル インコーポレイテッド リソソーム標的化ペプチドおよびその使用
CN102369023A (zh) 2008-12-16 2012-03-07 建新公司 寡糖-蛋白缀合物
EP3679942A1 (de) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
NZ713967A (en) * 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
US20110039300A1 (en) * 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
SI3998078T1 (sl) 2009-08-28 2026-02-27 Genzyme Corporation Encimsko nadomestno zdravljenje z naraščajočim odmerkom za zdravljenje pomanjkanja kisle sfingomielinaze
US8536148B2 (en) 2009-09-04 2013-09-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Disabling autophagy as a treatment for lysosomal storage diseases
WO2011034951A2 (en) * 2009-09-15 2011-03-24 The Regents Of The University Of California Assisted enzyme replacement therapy
FI3205351T3 (fi) 2010-04-23 2023-07-06 Alexion Pharma Inc Lysosomaalisen kertymätaudin entsyymi
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
AU2011270672B2 (en) 2010-06-25 2017-01-12 Shire Human Genetic Therapies, Inc. Treatment of Sanfilippo Syndrome type B
HRP20191923T1 (hr) 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
EP2595651B1 (de) 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Kodonoptimierte zelllinie für den mannoserezeptor-c vom typ 1 (mrc1) und anwendungen davon
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
KR20150038636A (ko) 2010-09-09 2015-04-08 시나게바 바이오파르마, 코포레이션 환자에서 리소좀 산 리파제 결핍증의 치료를 위한 리소좀 산 리파제의 용도
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
JP5665065B2 (ja) 2011-04-28 2015-02-04 国立大学法人大阪大学 リソソーム病治療用医薬組成物
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
LT2753346T (lt) 2011-09-07 2020-08-10 Mount Sinai School Of Medicine Ceramidazė ir ląstelių diferenciacija
SG10201510106PA (en) * 2011-10-12 2016-01-28 Synageva Biopharma Corp Recombinant human naglu protein and uses thereof
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
US9682129B2 (en) 2011-12-23 2017-06-20 Shire Human Genetic Therapies, Inc. Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
MX2014011836A (es) 2012-03-30 2015-03-09 Shire Human Genetic Therapies Administracion subcutanea de iduronato-2-sulfatasa.
SMT202100136T1 (it) 2012-05-03 2021-05-07 Amicus Therapeutics Inc Regimi posologici per il trattamento della malattia di pompe
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
CA3140358A1 (en) * 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014089487A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Methods and compositions for intrathecally administered treatment of mucupolysaccharidosis type iiia
AU2014218854B2 (en) 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
PT2968479T (pt) 2013-03-14 2019-08-07 Icahn School Med Mount Sinai Composições terapêuticas de ceramidase ácida e métodos de fabrico e utilização
US10751283B2 (en) 2014-01-14 2020-08-25 Capability Building, Inc. Liposomal rehydration salt formulation and associated methods of use
AR094658A1 (es) * 2014-01-14 2015-08-19 Fast Rehydration Llc Formulación de sales de rehidratación liposomal
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
AU2015252906C1 (en) 2014-05-01 2020-09-17 Bioasis Technologies Inc. p97-polynucleotide conjugates
EP3200816A1 (de) 2014-09-29 2017-08-09 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von mukopolysaccharidose iiib (mpsiiib)
CN114540327B (zh) 2014-09-30 2026-03-24 阿米库斯治疗学公司 具有增强的碳水化合物的高强度酸性α-葡糖苷酶
EP3827839B1 (de) 2015-07-20 2023-06-21 Shire Human Genetic Therapies, Inc. Behandlung der kognitiven beeinträchtigung von mucopolysaccharidose typ iiia durch intrathekale verabreichung von heparan-n-sulfatase
EP3383911B1 (de) 2015-12-02 2021-01-20 STCube & Co. Inc. Antikörper und moleküle die immunspezifisch an btn1a1 binden und therapeutische verwendungen davon
MX2018007330A (es) * 2015-12-15 2019-03-14 Genzyme Corp Vectores virales adeno-asociados para tratar mucolipidosis de tipo ii.
PL3397270T3 (pl) * 2015-12-30 2024-08-19 Green Cross Corporation Kompozycje do zastosowania w leczeniu zespołu huntera
KR20250007693A (ko) 2015-12-30 2025-01-14 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
JP2019509270A (ja) 2016-02-17 2019-04-04 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド アリールスルファターゼａのｃｎｓ送達のための方法および組成物
MX2018010196A (es) 2016-02-24 2018-11-19 Biomarin Pharm Inc Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
US10449230B2 (en) 2016-10-06 2019-10-22 The Regents Of The University Of California Polymyxin derived cell penetrating scaffolds
US11957713B2 (en) 2016-10-14 2024-04-16 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
US11357834B2 (en) * 2017-01-10 2022-06-14 Amicus Therapeutics, Inc. Recombinant α-galactosidase A for treatment of Fabry disease
CA3050690A1 (en) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for diagnosing and treating peroxisomal diseases
AU2018210853B2 (en) * 2017-01-17 2023-09-28 Children's Medical Center Corporation Compositions and methods for treating lysosomal storage diseases and disorders
EP3357489A1 (de) 2017-02-03 2018-08-08 Rheinische Friedrich-Wilhelms-Universität Bonn Mutierte arylsulfatase a
SMT202300187T1 (it) 2017-05-15 2023-07-20 Amicus Therapeutics Inc Alfa-glucosidasi acida umana ricombinante
CN111051346A (zh) 2017-05-31 2020-04-21 斯特库伯株式会社 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
KR20200026209A (ko) 2017-06-06 2020-03-10 주식회사 에스티큐브앤컴퍼니 Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법
KR101942093B1 (ko) * 2018-01-05 2019-01-24 인하대학교 산학협력단 만노시다제 억제제를 포함하는 고만노즈 타입 n-당쇄를 갖는 인간 리소좀 효소 생산용 조성물
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
EP4043562A1 (de) 2021-02-16 2022-08-17 Rheinische Friedrich-Wilhelms-Universität Bonn Mutierte arylsulfatase a mit erhöhter stabilität
EP4504953A4 (de) * 2022-04-05 2026-04-15 Astellas Gene Therapies Inc Potenztest für adeno-assoziierte viren und verwendungen davon
EP4518885A1 (de) 2022-05-05 2025-03-12 Amicus Therapeutics, Inc. Verfahren zur behandlung von morbus pompe
WO2023220649A2 (en) * 2022-05-10 2023-11-16 Mammoth Biosciences, Inc. Effector protein compositions and methods of use thereof
AR131256A1 (es) 2022-12-02 2025-03-05 Amicus Therapeutics Inc Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos
WO2024119091A1 (en) 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US583711A (en) * 1897-06-01 Detergent and process of producing same
US4140107A (en) 1972-12-28 1979-02-20 Erasmus University Rotterdam Echoscope for examination of objects
CH585793A5 (de) 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (de) 1974-05-02 1978-07-06
US3957578A (en) 1975-01-03 1976-05-18 Hokkaido Sugar Co., Ltd. Method for manufacture of α-galactosidase by microorganism
US4328215A (en) 1977-05-09 1982-05-04 The Johns Hopkins University Method of reducing or avoiding the mutagenic activity of drugs
NL7706429A (nl) 1977-06-10 1978-12-12 Univ Erasmus Werkwijze voor de bereiding van een geneesmid- del met angst en angstequivalenten opheffende werking en gevormd geneesmiddel met een derge- lijke werking.
US4195126A (en) 1977-10-04 1980-03-25 The Board Of Trustees Of The University Of Alabama Albumin-dye complex for fatty acid determination
USRE35770E (en) 1978-11-06 1998-04-14 Choay, S.A. Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them
IL61201A (en) 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them
US4332894A (en) 1980-08-15 1982-06-01 Purdue Research Foundation Conversion of guar gum to gel-forming polysaccharides by the action of α-galactosidase
US4496722A (en) 1981-05-01 1985-01-29 The Children's Medical Center Corporation Reporter compounds
US4659817A (en) 1981-05-01 1987-04-21 The Children's Medical Center Corporation Reporter compounds containing boron
DE3122216A1 (de) 1981-06-04 1982-12-23 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung eines mikroorganismus, welcher (alpha)-galactosidase, aber keine invertase bildet, so erhaltener mikroorganismus und seine verwendung
US4433946A (en) 1981-07-21 1984-02-28 Christianson Systems, Inc. Discharge system for grain handling apparatus
IT1140312B (it) 1981-12-03 1986-09-24 Anic Spa Procedimento per la produzione di alfa-galattosidasi e impieghi dell'enzima cosi' ottenuto
NL8105635A (nl) 1981-12-15 1983-07-01 Univ Erasmus Geneesmiddel met transplantaatafstotings- en/of immunologische ontstekingsremmende werking, alsmede werkwijze voor de remming van transplantaatafstoting en/of immunologische ontsteking.
US4987223A (en) 1981-12-23 1991-01-22 Choay S.A. Derivatives of the uronic acid
US4749570A (en) 1981-12-31 1988-06-07 The Governors Of The University Of Alberta Targeting conjugates of albumin and therapeutic agents
US4492761A (en) 1982-04-05 1985-01-08 Duke University Complement assay method
NL189547C (nl) 1983-04-12 1993-05-17 Univ Erasmus Stelsel voor het bepalen van de stroomsterkte van het hart van een patient.
SE440973B (sv) 1984-02-02 1985-09-02 Trelleborg Ab Anleggning for fiskodling i oppen sjo med flytkroppar ledbart forbundna med varandra och stabiliserade med en tyngdbelastad kjol anleggning for fiskodling i oppen sjo med flytkroppar ledbart forbundna med varandra och stabiliserade med en tyngdbelastad kjol
JPS60241884A (ja) 1984-05-15 1985-11-30 Tokyo Daigaku 自動サイクリング反応装置およびこれを用いる自動分析装置
US5001072A (en) 1984-05-23 1991-03-19 Icn Biomedicals Inc. Compositions and methods for multiple simultaneous immunoradiometric assay (IRMA) of analytes using radioisotope chelate labels
US5691181A (en) 1984-08-21 1997-11-25 Celltech Limited DNA encoding lipase from human gastric mucosal tissue
US4986274A (en) 1984-10-19 1991-01-22 Stephens John D Fetal anatomic sex assignment by ultrasonography during early pregnancy
US4639420A (en) 1984-11-21 1987-01-27 Schaffner Carl P Method for the immunoanalysis of cholesterol epoxides
US4615884A (en) 1985-04-09 1986-10-07 Vanderbilt University Method and vaccine for treatment of demyelinating diseases
JPH0669953B2 (ja) 1985-08-16 1994-09-07 日産化学工業株式会社 脳脊髄系神経栄養剤
CA1339101C (en) 1986-06-03 1997-07-29 Nicolaas Overbeeke Production of guar alpha-galactosidase and immunologically related alpha-galactosidases by host organisms transformed with recombinant dna methods
US5217865A (en) 1986-07-25 1993-06-08 The United States Of America As Represented By The Department Of Health And Human Services Screening for Tay-Sachs disease with cloned DNA for beta-hexosaminidase
FR2603804B1 (fr) 1986-09-17 1989-10-27 Jouveinal Sa Lipases et extraits lipasiques, leur procede de preparation et leur application en therapeutique
GB8630721D0 (en) 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
EP0832981A1 (de) 1987-02-17 1998-04-01 Pharming B.V. DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten
US5055401A (en) 1987-04-10 1991-10-08 Alko Ltd. Construction of new α-galactosidase producing yeast strains and the industrial application of these strains
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
JPS6460379A (en) 1987-08-28 1989-03-07 Toyo Jozo Kk Novel ganglioside ceramidase and production thereof
US5143841A (en) 1987-08-28 1992-09-01 Toyo Jozo Company, Ltd. Ganglioside ceramidase and process for producing same
DE3732871A1 (de) 1987-09-30 1989-04-20 Behringwerke Ag Chromogene substrate
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US4868042A (en) 1987-12-09 1989-09-19 Pall Corporation Antiwicking compositions and fabrics treated therewith
US5639939A (en) 1987-12-23 1997-06-17 The Board Of Trustees For The Leland Stanford Junior University Chimeric immunocompromised mammal comprosing vascularized fetal organ tissue
US5126247A (en) 1988-02-26 1992-06-30 Enzymatics, Inc. Method, system and devices for the assay and detection of biochemical molecules
GB8806892D0 (en) 1988-03-23 1988-04-27 Unilever Plc Lactams their synthesis & use in cosmetic compositions
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5929036A (en) 1989-03-08 1999-07-27 The Board Of Regents Of The University Of Oklahoma Ligand or GMP-140 selectin and methods of use thereof
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
DE3916729A1 (de) 1989-05-23 1990-12-06 Behringwerke Ag Fluorogene verbindungen und ihre verwendung
US5281394A (en) 1989-07-21 1994-01-25 Icn Biomedicals, Inc. Data collection and sample handling apparatus
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5060428A (en) 1990-02-09 1991-10-29 Resco Products, Inc. Prefabricated walls
US5089392A (en) 1990-03-30 1992-02-18 The United States Of America As Represented By Of The Department Of Health And Human Services Fluorogenic substrates for measurement of lysosomal enzyme activities within intact cells
US5061025A (en) 1990-04-13 1991-10-29 Eastman Kodak Company Hologon scanner with beam shaping stationary diffraction grating
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5316908A (en) 1990-07-13 1994-05-31 Life Technologies, Inc. Size markers for electrophoretic analysis of DNA
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5382524A (en) 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US5208148A (en) 1990-12-07 1993-05-04 Molecular Probes, Inc. Lipophilic fluorescent glycosidase substrates
US5260447A (en) 1991-02-15 1993-11-09 Sankyo Company, Limited Polyhydroxycyclopentane derivatives, their preparation and their therapeutic use
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5205917A (en) 1991-05-07 1993-04-27 Glyko, Inc. Fluorophore assisted carbohydrate electrophoresis diagnosis
EP0603205A4 (en) 1991-08-07 1995-10-18 Sinai School Medicine Methods for determining susceptibility to lead poisoning.
US5576424A (en) 1991-08-23 1996-11-19 Molecular Probes, Inc. Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
DE69229174T2 (de) 1991-08-23 1999-09-16 Molecular Probes, Inc. Verwendung von haloalkylderivaten von reportermolekülen zur analyse der metabolischen aktivität in zellen
US5242805A (en) 1991-08-23 1993-09-07 Molecular Probes, Inc. Long wavelength lipophilic fluorogenic glycosidase substrates
NL9101680A (nl) 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
US5433946A (en) 1991-10-11 1995-07-18 Health Research Inc. Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
AU2873292A (en) 1991-11-06 1993-06-07 Toronto Research Chemicals Inc. Immunostimulating swainsonine analogs
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
GB9207280D0 (en) 1992-04-02 1992-05-13 Unilever Plc Skin care method and composition
DE69312142T2 (de) 1992-04-02 1998-02-05 Philips Electronics Nv Verfahren zum Herstellen einer zugespitzten Elektrode
GB9207288D0 (en) 1992-04-02 1992-05-13 Unilever Plc Cosmetic composition
US5366883A (en) 1992-06-09 1994-11-22 Takara Shuzo Co., Ltd. α-amylase gene
US5578479A (en) 1992-06-09 1996-11-26 The Johns Hopkins University Alpha-amylase from hyperthermophilic archaebacterium
HU217543B (hu) 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US5420112A (en) 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
WO1994004672A1 (en) 1992-08-26 1994-03-03 Dnx Corp. Tetracycline repressor-mediated binary regulation system for control of gene expression in transgenic animals
US5449604A (en) 1992-10-21 1995-09-12 University Of Washington Chromosome 14 and familial Alzheimers disease genetic markers and assays
CA2147887A1 (en) 1992-10-30 1994-05-11 James W. Dennis Method for measuring glycosyltransferase activity
US5512471A (en) 1992-12-23 1996-04-30 The Curators Of The University Of Missouri Process for purifying an α-D-galactosidase isozyme from Coffea beans
US5667839A (en) 1993-01-28 1997-09-16 Collagen Corporation Human recombinant collagen in the milk of transgenic animals
DK38893D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Dna
AU688321B2 (en) 1993-04-21 1998-03-12 Institut Pasteur Biocompatible implant for the expression and secretion in vivo of a therapeutic compound
US5798366A (en) 1993-05-13 1998-08-25 Monsanto Company Method for treatment of CNS-involved lysosomal storage diseases
US5736360A (en) 1993-09-10 1998-04-07 The Trustees Of The University Of Pennsylvania Endothelial cell tropic compositions and methods of making and using the same
GB9319104D0 (en) 1993-09-15 1993-11-03 Unilever Plc Skin care method & composition
EP0719133A1 (de) 1993-09-15 1996-07-03 Unilever Plc Hautpflegeverfahren und zusammensetzung
US5491076A (en) 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
US5405751A (en) 1994-01-12 1995-04-11 Schering Corporation Prenatal diagnosis by cytokine-induced proliferation of fetal T-cells
EP0744901B1 (de) 1994-02-16 2001-12-05 Pharming Intellectual Property BV Isolierung von lactoferrin aus milch
US5627171A (en) 1994-04-11 1997-05-06 Oncomembrane, Inc. Sphingosine-1-phosphate/trimethylsphingosine composition
ES2276393T3 (es) 1994-04-25 2007-06-16 Genentech, Inc. Cardiotrofina y sus usos.
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
JPH09511405A (ja) 1994-09-08 1997-11-18 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング レトロウイルスベクターハイブリッド及びその遺伝子転移のための使用
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5707865A (en) 1994-12-21 1998-01-13 Kohn; Donald B. Retroviral vectors for expression in embryonic cells
US5792647A (en) 1995-02-13 1998-08-11 The Johns Hopkins University Bacterial catabolism of chitin
JPH08271784A (ja) 1995-03-30 1996-10-18 Canon Inc 視線検出機能付き光学機器
US5871946A (en) 1995-05-18 1999-02-16 Coulter Corporation Method for determining activity of enzymes in metabolically active whole cells
US5663254A (en) 1995-05-22 1997-09-02 The Johns Hopkins University Synthesis of high mannose glycopolymers
US5704910A (en) 1995-06-05 1998-01-06 Nephros Therapeutics, Inc. Implantable device and use therefor
US5928928A (en) 1995-06-07 1999-07-27 Universiteit Van Amsterdam Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US5663076A (en) 1995-08-08 1997-09-02 Lsi Logic Corporation Automating photolithography in the fabrication of integrated circuits
WO1997007226A1 (en) 1995-08-17 1997-02-27 Introgene B.V. Poly(organo)phosphazenes for use in synthetic transfection systems
ES2326705T3 (es) 1995-09-14 2009-10-16 Virginia Tech Intellectual Properties, Inc. Produccion de enzimas lisosomicas en sistemas de expresion basados en plantas.
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US6048964A (en) 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5830916A (en) 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
US5719031A (en) 1996-08-14 1998-02-17 Molecular Probes, Inc. Dye labeled polymers as reagents for measuring polymer degradation
US5830850A (en) 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
JPH1080280A (ja) 1996-09-09 1998-03-31 Shimadzu Corp 核酸合成法
US5773236A (en) 1997-04-25 1998-06-30 Molecule Probes, Inc. Assay for glutathiane transferase using polyhaloaryl-substituted reporter molecules
US5939279A (en) 1997-09-18 1999-08-17 The Board Of Trustees Of The University Of Arkansas Inhibition of bacterial binding by high-mannose oligosaccharides
JP2002508167A (ja) * 1997-12-18 2002-03-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １１０個のヒト分泌タンパク質
US6534300B1 (en) * 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase

Also Published As

Publication number Publication date
AU7330300A (en) 2001-04-17
US20020150981A1 (en) 2002-10-17
US20060073498A1 (en) 2006-04-06
BR0014514A (pt) 2002-07-23
EP1224266B1 (de) 2007-09-12
US6534300B1 (en) 2003-03-18
US6642038B1 (en) 2003-11-04
CA2383217C (en) 2013-11-19
US20080176285A1 (en) 2008-07-24
DE60036395T2 (de) 2008-06-12
WO2001019955A2 (en) 2001-03-22
US20050089869A1 (en) 2005-04-28
DE60036395D1 (de) 2007-10-25
AU783224B2 (en) 2005-10-06
CA2383217A1 (en) 2001-03-22
WO2001019955A3 (en) 2001-10-04
US6537785B1 (en) 2003-03-25
US20020025550A1 (en) 2002-02-28
US6670165B2 (en) 2003-12-30
US6861242B2 (en) 2005-03-01
US7067127B2 (en) 2006-06-27
EP1224266A2 (de) 2002-07-24
US7371366B2 (en) 2008-05-13
MXPA02002901A (es) 2003-10-14
EP1224266A4 (de) 2003-05-28
JP2003509043A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
ATE373086T1 (de) Enzyme des auf die lysosomen gerichteten weges
WO2005049842A3 (en) Improved targeted dna insertion in plants
MXPA03007527A (es) Enzimas que tienen actividad de alfa amilasa y metodos de uso de las mismas.
ATE308550T1 (de) Verwendungen von sulfatierten fuko- oligosacchariden zum pflanzenschutz
DE60129549D1 (de) Verbesserte nukleinsäure-modifizierende enzyme
AU2002366285A8 (en) Ides, an igg-degrading enzyme of streptococcus pyogenes
ATE357272T1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
TR200103221T2 (tr) Heterosiklik olarak ikame edilmiş benzimidazoller, bunların üretimi ve uygulanması
WO1999057325A3 (en) Enzymes mixture
TR200101400T2 (tr) 2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
WO2004029277A3 (en) Oligonucleotide conjugates
WO2006063055A3 (en) Enzyme conjugates for use as detoxifying agents
WO2004027056A3 (en) Methods of use for thermostable rna ligases
AU2003235506A1 (en) Targeted enzymes and methods of making and using targeted enzymes.
GB0020331D0 (en) Enzyme
WO2002077184A3 (en) Oligonucleotide conjugates
AU2487602A (en) Isolated luciferases and the use thereof
MXPA02003360A (es) Transacilasas de la ruta biosintetica de paclitaxel.
ATE356212T1 (de) O-fukosyltransferase
PT1196606E (pt) Enzima litica
WO2001060986A3 (en) Esterase enzymes having selective activity
DE60022083D1 (de) Neutralisierungsmittel für toxin der zur gattung clostridium gehörende mikroorganismen
HUP0400150A2 (en) Saponin-digesting enzymes, genes thereof and soyasapogenol b mass production system
ES2164545A1 (es) Enzimas con actividad beta-(1,6)-endoglucanasa.
WO2004072241A3 (en) Compositions and methods for cleaving iap

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties